Thermo Fisher Scientific (NYSE:TMO) CEO Marc Casper Sells 10,000 Shares

Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc Casper sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,982,284.75. The trade was a 7.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Thermo Fisher Scientific Trading Down 0.1%

Shares of TMO stock opened at $628.69 on Tuesday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The firm’s 50 day moving average price is $545.64 and its two-hundred day moving average price is $509.60. The stock has a market cap of $232.46 billion, a price-to-earnings ratio of 33.82, a price-to-earnings-growth ratio of 2.56 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Barclays upped their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective on the stock. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. Finally, Royal Bank Of Canada upped their price objective on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $619.41.

Institutional Investors Weigh In On Thermo Fisher Scientific

Institutional investors have recently modified their holdings of the stock. Tsfg LLC increased its holdings in Thermo Fisher Scientific by 20.4% in the second quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock valued at $56,000 after buying an additional 19 shares during the last quarter. Elyxium Wealth LLC grew its position in shares of Thermo Fisher Scientific by 1.9% in the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock worth $613,000 after acquiring an additional 20 shares in the last quarter. Renasant Bank increased its holdings in shares of Thermo Fisher Scientific by 1.0% in the 2nd quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock valued at $970,000 after acquiring an additional 20 shares during the last quarter. Revolve Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. Finally, Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. lifted its stake in Thermo Fisher Scientific by 0.7% during the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock worth $1,436,000 after purchasing an additional 20 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.